A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs
The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.
Read original article on Inc.com →Related news
-
Japan's Most Famous Tuna Buyer Says He Turned Somali Pirates into Fishermen
-
Stop watching... start earning
- OpenAI mistranslated mathematics into code for its Navier-Stokes proof
-
I Refused to Borrow Money for My Business. Changing My Mind Is How I Built a Multi-Million Dollar Exit
-
San Francisco’s First No Phones Party Revealed What Tech Can’t Automate
-
Micro1’s $1 Billion Bet Isn’t on Better Models. It’s on Your Company’s Data
-
7 Hot Products Consumers Are Buying Right Now
-
Souplantation Closed Every Restaurant in 2020. Now It’s Coming Back—but Not Because Buffets Are Booming